ClinicalTrials.gg
TerminatedNCT03986944Updated Apr 2, 2025Results posted

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

A Phase 3 interventional study of 75 mg linzagolix tablet and 200 mg linzagolix tablet in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Terminated at 112 sites in 3 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study halted due to the significant enrollment challenges encountered since its beginning. Screening and enrollment have been impacted by the COVID pandemic and more importantly by changes in the diagnosis and treatment of women with endometriosis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2019
with 1 other
Phase 3
5 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
9 of 10
Kissei Pharmaceutical Co., Ltd.

Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2019, is one of 5 in phase 3, and was the 6th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).

Read the detailed description

This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and 200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the management of moderate to severe EAP in 450 women.

Eligible subjects who have completed the 6-month treatment period may enter a separate extension study for 6 additional months of active treatment (no placebo control). Subjects who do not continue in the extension study will enter a 6 month treatment-free follow-up phase.

03

Conditions studied

  • Endometriosis

Keywords

  • Dysmenorrhea
  • Dyspareunia
  • Dyschezia
  • Non-menstrual pelvic pain
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

The subject must have:

  • Her most recent surgical and - if available - histological diagnosis of pelvic endometriosis up to 10 years before screening.
  • Moderate to severe endometriosis-associated pain during the screening period.
  • Regular menstrual cycles.
  • ≥ 18 kg/m2 at the screening visit.

Key Exclusion Criteria:

The subject will be excluded if she:

  • Is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of entry into the screening period.
  • Has had a surgical history of any major abdominal surgery within 6 months or any interventional surgery for endometriosis performed within a period of 2 months before screening.
  • Did not respond to prior treatment with GnRH agonists or GnRH antagonists for endometriosis.
  • Has a history of, or known, osteoporosis or other metabolic bone disease.
  • Has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic or other chronic therapy which would interfere with the assessment of endometriosis-associated pain.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Linzagolix 75 mg

    Drug: 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule

  • Experimental
    Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)

    Drug: 200 mg linzagolix tablet · Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg) · Drug: Placebo tablet to match 75 mg linzagolix tablet

  • Placebo comparator
    Placebo

    Drug: Placebo tablet to match 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule

Interventions

  • For oral administration once daily

  • For oral administration once daily

  • DrugAdd-back capsule (E2 1 mg / NETA 0.5 mg)

    Drug page: Estradiol

    For oral administration once daily

  • DrugPlacebo tablet to match 75 mg linzagolix tablet

    For oral administration once daily

  • DrugPlacebo tablet to match 200 mg linzagolix tablet

    For oral administration once daily

  • DrugPlacebo capsule to match Add-back capsule

    For oral administration once daily

06

What researchers measure

Primary outcomes

  1. Dysmenorrhea

    Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea (DYS) measured on a 4-point Verbal Rating Scale (VRS) using an electronicdiary * The 4-point VRS scale for DYS ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the pain of DYS.

    Time frame: Baseline to Month 3

  2. Non-menstrual Pelvic Pain

    Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain (NMPP) measured on a 4-point Verbal Rating Scale (VRS) using anelectronic diary * The 4-point VRS scale for NMPP ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the NMPP.

    Time frame: Baseline to Month 3

07

Results

Posted Oct 29, 2024
Limitations and caveats
In this study, two co-primary endpoints, 1) clinically meaningful reduction up to Month 3 and 2) a stable/decreased use of analgesics for EAP of DYS \& NMPP, were planned. Although the Responder Threshold Analysis was needed to evaluate the effectiveness of reducing pain, the clinical-meaningful response threshold couldn't be calculated due to the early study termination and the low number of subjects randomized. So, we showed the limited data of the changes up to Month 3 in DYS \& NMPP instead.

Participant flow

Of the 492 subjects screened, 85 were randomized. Between randomization and Day 1 (i.e., first day of dosing), 1 subject in the placebo group discontinued due to protocol deviation. Thus, 84 randomized subjects were treated and comprised the Safety Analysis Set.

Participant flow — Overall Study
MilestoneLGX 75 mgLGX 200 mg+ABTPlacebo
Started282927
Completed13108
Not completed151919
Withdrew: Adverse event123
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject355
Withdrew: Study termination101010
Withdrew: Discontinuation after moving to follow-up period [study termination per sponsor]100
Withdrew: Discontinuation after moving to follow-up period [subject's request (family issue)]010

Outcome measures

PrimaryDysmenorrhea

Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea (DYS) measured on a 4-point Verbal Rating Scale (VRS) using an electronicdiary * The 4-point VRS scale for DYS ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the pain of DYS.

Time frame:
Baseline to Month 3
Reported as:
Mean · score on a scale
Dysmenorrhea
score on a scaleLGX 75 mgLGX 200 mg+ABTPlacebo
Dysmenorrhea-0.5 ± 0.50.0 ± 0.00.5 ± 0.5
PrimaryNon-menstrual Pelvic Pain

Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain (NMPP) measured on a 4-point Verbal Rating Scale (VRS) using anelectronic diary * The 4-point VRS scale for NMPP ranges from 0 to 3 (0: No pain; 1: Mild pain; 2: Moderate pain; 3: Severe pain). * A negative change in scores would be indicative of an improvement in the NMPP.

Time frame:
Baseline to Month 3
Reported as:
Mean · score on a scale
Non-menstrual Pelvic Pain
score on a scaleLGX 75 mgLGX 200 mg+ABTPlacebo
Non-menstrual Pelvic Pain-1.0 ± 0.00.0 ± 0.00.0 ± 0.0

Adverse events

Collected over - Treatment Period: 6 months (Day 1 to Month 6) - Follow-up Period: 6 months (Month 6 to Month 6 FU). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LGX 75 mg0/28 (0%)0/28 (0%)10/28 (35.7%)
LGX 200 mg+ABT0/29 (0%)0/29 (0%)16/29 (55.2%)
Placebo0/27 (0%)0/27 (0%)12/27 (44.4%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLGX 75 mgLGX 200 mg+ABTPlacebo
COVID-19Infections and infestations0/281/293/27
NauseaGastrointestinal disorders2/283/293/27
HeadacheNervous system disorders2/282/292/27
Chest discomfortGeneral disorders0/280/292/27
DizzinessNervous system disorders2/282/290/27
Ovarian cystReproductive system and breast disorders2/280/290/27
FatigueGeneral disorders2/280/291/27
Upper respiratory tract infectionInfections and infestations0/282/290/27
DiarrhoeaGastrointestinal disorders0/282/290/27
Vaginal haemorrhageReproductive system and breast disorders0/282/290/27

Baseline characteristics

Amongst the 85 randomized subjects, 84 subjects were included in the safety analysis set (1 subject in the placebo group discontinued due to protocol deviation).

Age, Categorical
Age, Categorical(Participants)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
<=18 years0000
Between 18 and 65 years28292784
>=65 years0000
Age, Continuous
Age, Continuous(years)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Mean32.6 ± 7.233.4 ± 6.432.1 ± 6.932.7 ± 6.8
Age, Customized
Age, Customized(years)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Median32.5 (28.0 to 36.0)34.0 (29.0 to 37.0)31.0 (26.0 to 37.0)33.0 (28.0 to 37.0)
Sex: Female, Male
Sex: Female, Male(Participants)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Female28292784
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Hispanic or Latino712928
Not Hispanic or Latino20171855
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
American Indian or Alaska Native0011
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American41510
White22272069
More than one race0101
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Canada1203
Puerto Rico4206
United States23252876
Weight
Weight(kg)LGX 75 mgLGX 200 mg+ABTPlaceboTotal
Mean78.130 ± 16.90476.540 ± 20.20771.280 ± 16.05075.379 ± 17.885

1 further baseline measures are reported on the registry.

08

Study locations

112 sites
  • Birmingham OBGYN / ID # 740
    Birmingham, Alabama 35205, United States
  • Mesa Obstetricians and Gyneocologists / ID # 790
    Mesa, Arizona 85209, United States
  • Precision Trials AZ, LLC / ID # 783
    Phoenix, Arizona 85032, United States
  • Quality of LIfe Medical & Research Center, LLC / ID # 813
    Tucson, Arizona 85712, United States
  • Visions Clinical Research-Tucson / ID # 754
    Tucson, Arizona 85712, United States
  • Lynn Institute of the Ozarks / ID # 826
    Little Rock, Arkansas 72205, United States
  • Applied Research Center of Arkansas / ID # 735
    Little Rock, Arkansas 72212, United States
  • Join Clinical Trials / ID # 778
    Huntington Park, California 90255, United States
  • Long Beach Clinical Trials, LLC / ID # 768
    Long Beach, California 90806, United States
  • Matrix Clinical Research / ID # 751
    Los Angeles, California 90057, United States
  • Futura Research, Org / ID # 781
    Norwalk, California 90650, United States
  • National Research Institute / ID # 805
    Panorama City, California 91402, United States
  • Precision Research Institute / ID # 792
    San Diego, California 92114, United States
  • MD Strategies Research Centers / ID # 765
    San Diego, California 92119, United States
  • Downtown Women's Health Care / ID # 718
    Denver, Colorado 80209, United States
  • Center for Women's Health / ID # 761
    Greenwood Village, Colorado 80111, United States
  • Physicians Research Options, LLC / Red Rocks Ob/Gyn / ID # 732
    Lakewood, Colorado 80228, United States
  • Dr. David I. Lubetkin, LLC / ID # 703
    Boca Raton, Florida 33486, United States
  • Helix Biomedics Clincial Research, LLC / ID # 750
    Boynton Beach, Florida 33435, United States
  • Accel Research Sites, DeLand Clinical Research Unit / ID # 713
    DeLand, Florida 32720, United States
  • Universal Axon Clinical Research / ID # 769
    Doral, Florida 33166, United States
  • Clinical Neuroscience Solutions, Inc. / ID # 773
    Jacksonville, Florida 32256, United States
  • South Florida Clinical Research Institute / ID # 747
    Margate, Florida 33063, United States
  • Coral Way Research / ID # 799
    Miami, Florida 33135, United States
  • Suncoast Research Group, LLC / ID # 756
    Miami, Florida 33135, United States
  • Biotech Pharmaceutical Group LLC / ID # 786
    Miami, Florida 33155, United States
  • La Salud Research Clinic, Inc. / ID # 824
    Miami, Florida 33155, United States
  • Suncoast Research Associates, LLC / ID # 760
    Miami, Florida 33176, United States
  • LCC Medical Research Institute / ID # 814
    Miami, Florida 33196-1554, United States
  • Global Health Research Center, Inc. / ID # 787
    Miami Lakes, Florida 33016, United States
  • Sensible Healthcare / ID # 749
    Ocoee, Florida 34761, United States
  • A Premier Medical Research of Florida, LLC / ID # 752
    Orange City, Florida 32763, United States
  • Clinical Neuroscience Solutions, Inc. / ID # 731
    Orlando, Florida 32801, United States
  • Omega Research Orlando, LLC / ID # 785
    Orlando, Florida 32806-1133, United States
  • Clinical Associates of Orlando, LLC / ID # 779
    Orlando, Florida 32806, United States
  • Synexus Clinical Research US, Inc. / ID # 725
    Orlando, Florida 32806, United States
  • Physician Care Clinical Research LLC / ID # 810
    Sarasota, Florida 34239, United States
  • University of South Florida / ID # 738
    Tampa, Florida 33606, United States
  • GCP Clinical Research, LLC / ID # 825
    Tampa, Florida 33609, United States
  • Atlanta Women's Research Institute, Inc. / ID # 727
    Atlanta, Georgia 30342, United States
  • Sonara Clinical Research, LLC / ID # 720
    Meridian, Idaho 83646, United States
  • Moore Health Wellness Research Institute, LLC / ID # 795
    Chicago, Illinois 60605, United States
  • Providea Health Partners LLC / ID # 734
    Evergreen Park, Illinois 60805, United States
  • Cypress Medical Research Center, LLC / ID # 755
    Wichita, Kansas 67226, United States
  • Horizon Research Group of Opelousas, LLC / ID # 757
    Eunice, Louisiana 70535-5100, United States
  • Praetorian Pharmaceutical Research / ID # 739
    Marrero, Louisiana 70072, United States
  • Women Under Study, LLC / ID # 820
    New Orleans, Louisiana 70125, United States
  • Johns Hopkins University, School Of Medicine / ID # 816
    Baltimore, Maryland 21205, United States
  • Pharmasite Research Inc / ID # 838
    Baltimore, Maryland 21208, United States
  • Continental Clinical Solutions, LLC / ID # 777
    Towson, Maryland 21204, United States
  • NECCR Fall River, LLC / Id # 712
    Fall River, Massachusetts 02720, United States
  • Onyx Clinical Research / ID # 793
    Flint, Michigan 48532, United States
  • CMEP/CMU health / ID # 812
    Saginaw, Michigan 48602, United States
  • Valley OBGYN / ID # 704
    Saginaw, Michigan 48602, United States
  • Saginaw Valley Medical Research Group, LLC / ID # 743
    Saginaw, Michigan 48604, United States
  • Office of Edmond Pack, MD / Id # 818
    Las Vegas, Nevada 89113, United States
  • Lawrence OB/GYN clinical Research, LLC / ID # 742
    Lawrenceville, New Jersey 08648, United States
  • Albuquerque Clinical Trials, Inc. / ID # 707
    Albuquerque, New Mexico 87102, United States
  • Carolina Institute for Clinical Research / ID # 728
    Fayetteville, North Carolina 28304, United States
  • Unified Women's Clinical Research - Green Valley OBGYN / ID # 719
    Greensboro, North Carolina 27408, United States
  • Eastern Carolina Women's Center / Id # 794
    New Bern, North Carolina 28562, United States
  • Unified Women's Clinical Research - Raleigh / Id # 714
    Raleigh, North Carolina 27607, United States
  • Carolina Medical Trials, LLC / ID # 788
    Winston-Salem, North Carolina 27103, United States
  • ClinOhio Research Services, LLC / ID # 722
    Columbus, Ohio 43213, United States
  • Complete Healthcare for Women / ID # 801
    Columbus, Ohio 43213, United States
  • Wright State Physicians / ID # 733
    Dayton, Ohio 45409, United States
  • Hilltop OBGYN / ID # 711
    Franklin, Ohio 45005, United States
  • Oregon Health & Science University / ID # 791
    Portland, Oregon 97239, United States
  • OB/GYN Associates of Erie / ID # 706
    Erie, Pennsylvania 16507, United States
  • Penn State Health Milton S. Hershey Medical Center / ID # 804
    Hershey, Pennsylvania 17033, United States
  • The Clinical Trial Center / ID # 744
    Jenkintown, Pennsylvania 19046, United States
  • VitaLink Research - Upstate / ID # 789
    Greenville, South Carolina 29615, United States
  • Clinical Trials of South Carolina / ID # 741
    North Charleston, South Carolina 29406, United States
  • VitaLink Research Spartanburg / ID # 753
    Spartanburg, South Carolina 29303, United States
  • Seasons at Bristol / ID # 705
    Bristol, Tennessee 37620, United States
  • WR-ClinSearch, LLC / ID # 821
    Chattanooga, Tennessee 37421, United States
  • University of Tennessee Medical Center / ID # 780
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions, Inc / ID # 772
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates Inc / ID # 802
    Nashville, Tennessee 37203, United States
  • Women Partners in Health / ID # 836
    Austin, Texas 78705, United States
  • Austin Area ObGyn PLLC / ID # 701
    Austin, Texas 78758, United States
  • Christina Sebestyen MD, P.A. dba OBGYN North / ID # 764
    Austin, Texas 78758, United States
  • Christus St. Elizabeth Gadolin Research, LLC / ID # 774
    Beaumont, Texas 77702, United States
  • HCWC dba DiscoveryClinical Trials / ID # 771
    Dallas, Texas 75231, United States
  • UT Southwestern Medical Center / ID # 823
    Dallas, Texas 75390, United States
  • Signature Gyn Services / ID # 726
    Fort Worth, Texas 76104, United States
  • Georgetown OB/GYN / ID # 770
    Georgetown, Texas 78626, United States
  • Ventavia Research Group, LLC / ID # 729
    Houston, Texas 77008, United States
  • Vilo Research Group / ID # 709
    Houston, Texas 77017, United States
  • UT Health Clinical Res Ctr / ID # 828
    Houston, Texas 77024, United States
  • TMC Life Research, Inc. / ID # 809
    Houston, Texas 77054, United States
  • MacArthur OB-Gyn Research / ID # 840
    Irving, Texas 75062, United States
  • Medical Colleagues of Texas / ID # 819
    Katy, Texas 77450, United States
  • FMC Science / ID # 730
    Lampasas, Texas 76550, United States
  • Maximos OB/GYN / ID # 737
    League City, Texas 77573, United States
  • DCT-McAllen Primary Care Research, LLC dba Discovery Clinical Trials / ID # 803
    McAllen, Texas 78503, United States
  • DCT-AACT, LLC dba Discovery Clinical Trials / ID # 815
    Pflugerville, Texas 78660, United States
  • Northeast Clinical Research of San Antonio, LLC / ID # 710
    Schertz, Texas 78154, United States
  • Physicians Research Options PRO / ID # 766
    Draper, Utah 84020, United States
  • Physicians' Res Options - PG / ID # 833
    Pleasant Grove, Utah 84062, United States

Showing the first 100 of 112 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jan 2021, 19 months.

Results were first posted in Oct 2024, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2019
First posted
Jun 14, 2019
StartActual
May 23, 2019
Primary completionActual
Jan 6, 2021
CompletionActual
Feb 16, 2021
Results first posted
Oct 29, 2024
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03986944
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
May 23, 2019
Primary completion
Jan 6, 2021
Completion
Feb 16, 2021
Results posted
Oct 29, 2024
Last update
Apr 2, 2025

Study contacts

Lecomte
study director · ObsEva SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion